Immunocore raises $75M C round on back of Phase III uveal melanoma readout

On the cusp of seeking to become a commercial cancer company, Immunocore raised $75 million in a series C round.

The news comes less than two months after Oxford, U.K.-based Immunocore Ltd. announced the first positive outcomes data for a bispecific in solid tumors. In November, Immunocore said tebentafusp met the primary endpoint of overall survival in an interim analysis of a Phase III trial in patients with metastatic uveal melanoma (HR=0.51; p<0.0001)...